and aTB/HIV 1 groups, respectively. No significant differences were observed in the overall magnitude of IFN-g 1 responses between the four groups (data not shown).
We first compared the activation profile of IFN-g 1 Mtbspecific CD4
1 T cells between the four groups ( Figure 1A ). As previously shown (5) , in HIV-uninfected persons, HLA-DR, Ki67, and CD38 expression on IFN-g 1 Mtb-specific CD4 1 T cells was significantly higher in aTB participants than in those with LTBI ( Figure 1B) . Interestingly, although HLA-DR expression on Mtb-specific CD4
1 T cells in the LTBI/HIV 1 group (median, 41.7%; IQR, 25.7-54.6%) was significantly higher than in the LTBI/HIV 2 group (median, 13.7%; IQR, 8.9-27.5%), HLA-DR expression on these cells was significantly further increased in HIV-infected individuals with aTB (median, 84%; IQR, 73.7-87.9%) ( Figure 1B ). Additional analyses showed that in LTBI/HIV 1 individuals, HLA-DR expression on Mtb-specific CD4
1 T cells mirrors HLA-DR expression in the whole CD4 compartment (P = 0.02; r = 0.56), but this association was not apparent in aTB/HIV 1 individuals (data not shown). Unlike HLA-DR, Ki67 and CD38 expression levels were comparable between HIV-uninfected and HIVinfected individuals with LTBI. In HIV-infected persons with aTB, Ki67 expression on IFN-g 1 Mtb-specific CD4 1 T cells was significantly higher (P , 0.0001) than in LTBI, whereas the up-regulation of CD38 was more modest between these two groups (P = 0.03). Of note, in the aTB/HIV 1 group, the expression of CD38 was significantly higher in individuals with a positive smear when compared with smear-negative participants (P = 0.01; data not shown), suggesting that CD38 expression could reflect bacterial load. To assess the accuracy of these markers to discriminate between LTBI and aTB status, receiver operating characteristic curves and crossover plots were performed. Figure 1C shows the data for HLA-DR; area under the curve (AUC) and P values reflect that HLA-DR expression on IFN-g 1 Mtb-specific CD4 1 T cells distinguishes LTBI and aTB in both the HIV 2 and HIV 1 groups (AUC = 0.98 [P , .0001]; and AUC = 0.9 [P , 0.0001], respectively). However, the optimum cutoff values discriminating LTBI from aTB were distinct for HIV-uninfected (40%) and HIV-infected (70%) individuals. In our experimental setting, the expression of Ki67 and CD38 was less robust to differentiate TB status in HIV-uninfected (AUC = 0.896 [P = 0.00017], cutoff = 1.4%; AUC = 0.858 [P = 0.0007], cutoff = 4%, respectively) and HIV-infected (AUC = 0.89 [P = 0.0002], cutoff = 2.4%; AUC = 0.72 [P = 0.026], cutoff = 5%, respectively) individuals (data not shown). Our data were comparable to those of Adekambi and colleagues (5) despite disparity in the cutoff value for these markers, which could be explained by flow-cytometry technical differences.
The polyfunctional profile of Mtb-specific CD4 1 T cells has also been shown to discriminate between LTBI and aTB in HIV-uninfected individuals (2, 3), but conflicting data exist for HIV-infected persons (8) (9) (10) . Thus, we compared the profile of ESAT-6/CFP-10-specific CD4
1 T cells on the basis of their capacity to secrete IFN-g, TNF-a, and/or IL-2, between the four groups ( Figure 2A ). HIV-uninfected individuals with LTBI were T cells were observed; these differences could arise from significant disparities in the age, ethnicity, and TB diagnosis in the study cohorts. Receiver operating characteristic curve analyses ( Figure 2C) show that the proportion of IFN-g In summary, these data show that HLA-DR expression on IFN-g 1 Mtb-specific CD4 1 T cells represents a robust marker to distinguish between LTBI and aTB in both HIV-uninfected and antiretroviral therapy-naive HIV-infected individuals. This suggests that despite HIV-induced systemic immune activation, active bacterial replication promotes further up-regulation of HLA-DR on Mtb-specific CD4 1 T cells. On the contrary, the polyfunctional profile of Mtb-specific CD4
1 T cells associated with TB status solely in HIV-uninfected individuals, suggesting HIV infection may alter the secretion potential and/or localization of Mtb-specific CD4
1 T cells even in the absence of bacterial replication. One main limitation of such assays, requiring cell stimulation to identify Mtb-specific CD4
1 T cells, is that the analysis is restricted to individuals with detectable Mtb responses. Inclusion of additional immunodominant Mtb antigens could improve the "coverage" of Mtb responders. Further experiments will be needed to confirm these data in a larger study including HIV-infected participants receiving antiretroviral treatment. Nevertheless, this study confirms that HLA-DR expression could represent an important alternate tool to assess TB status in HIVuninfected individuals and expand this finding to HIV-infected subjects. n
